Regeneron Pharmaceuticals heads into September with shorts retreating sharply and the Street lifting targets even as the consensus stays cautious.
The most striking move this week is in short positioning. Bears have cut their exposure almost in half over the past month — short interest dropped 28% in a single week to reach 2.4% of free float, down from around 3.5% just ten days earlier. That's a meaningful cover, not a gradual drift. The shift began around August 25, when shares held steady near current levels, suggesting shorts closed out rather than got squeezed. At just 2.4% of float, the short base is now small enough that it adds little to the fundamental story either way.
The lending market confirms there's no pressure here. Borrow availability is essentially unlimited — the lending pool has tens of millions of shares unallocated — and the cost to borrow collapsed this week to 0.10%, down from around 0.50% for most of August. That's the cheapest it's been in six weeks. When both borrow cost and short interest fall together, the read is straightforward: bears are walking away, not being forced out. The ORTEX short score eased to 32.7 from 36 two weeks ago, tracking that same direction.
Options traders, meanwhile, have turned incrementally more bullish than usual. The put/call ratio dipped to 0.79, below its 20-day average of 0.85 — a modest but consistent signal. That reading is near the lower end of the past year's range (52-week low: 0.44, high: 1.13), placing options positioning on the lighter-hedged side of the historical spectrum. Nothing extreme, but it reinforces the picture: short sellers and options markets are both leaning away from the defensive posture of a few weeks ago.
The Street is broadly in the same mood, even if the consensus rating remains a hold. Following the strong Q2 print — the stock jumped nearly 10% on July 30 and added another 11% over the subsequent five days — analysts across the board lifted targets. Leerink Partners raised its target to $824 from $641 on August 17, sitting almost precisely at the current price of $823.82. Guggenheim is more constructive, maintaining Buy with a $1,030 target. Morgan Stanley and Wells Fargo both lifted to the mid-$700s while staying at Equal-Weight. The pattern: everyone acknowledges the Q2 beat, but the majority aren't willing to chase here. Bull case rests on marketed-product diversity, Dupixent royalties, and a pipeline that still has multiple shots on goal despite the LAG-3 phase III miss. Bear case centres on Eylea biosimilar erosion and the wider pipeline stumbles that have clouded the company's execution narrative.
Valuation has re-rated meaningfully. The trailing P/E moved from around 13.7 to 13.9 over the past 30 days — a modest expansion — while EV/EBITDA ticked down slightly to 8.9x, making the stock cheaper on a cash-flow basis even as the price recovered. Forward earnings momentum is the standout factor: the 12-month forward EPS growth rank scores in the 97th percentile of the universe, a reflection of the sharp upward revision cycle following Q2. Dividend yield is a minor feature at just over 0.5%, but the dividend score ranks in the 96th percentile — unusual for a biotech and a sign of the income-oriented institutional base.
Dodge & Cox added nearly 413,000 shares in Q2, bringing their stake to 4.9% of shares. Wellington Management added 257,000 over the same period. These are value-oriented, long-duration holders — their continued accumulation is a counterweight to the pipeline-risk narrative. BlackRock and Vanguard hold roughly 16% of shares combined and showed modest additions in July.
The next scheduled earnings are October 30. Regeneron has beaten estimates in each of the last two prints, with average next-day moves of around 8% and five-day moves of around 11%. With short interest now thin, the stock is less coiled for a squeeze-driven reaction in either direction than it was going into Q2. What matters for October 30 is whether the forward-EPS revision cycle — currently scoring near the top of the universe — continues to hold, and whether Eylea's trajectory in a competitive market stabilises or deteriorates further into year-end.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
